Jakarta –
The role of PT Bio Farma (Persero) as a state-owned pharmaceutical company continues to be in the spotlight in efforts to strengthen national health resilience. As a BUMN holding in the pharmaceutical sector, Bio Farma not only focuses on drug production, but is also the backbone in providing vaccines and developing life science products in Indonesia. This company is considered to have a strategic contribution in ensuring equal access to health services for the community.
Bio Farma also acts as a pillar of national health resilience through support for immunization programs, both domestically and globally. Not only meeting domestic needs, this company also exports vaccines and biotechnology products to more than 150 countries. This contribution shows Bio Farma’s position as an important player in the global health supply chain while strengthening Indonesia’s reputation in the pharmaceutical sector.
Apart from that, Bio Farma continues to encourage innovation in the life sciences sector, including the development of vaccines and research-based biotechnology. Quoted from the Kemdiktisaintek page, Bio Farma is capable of producing hundreds of millions of vaccine doses every year, even reaching billions of doses for certain types such as the polio vaccine which is distributed globally. This production capacity is key in maintaining vaccine availability as well as supporting preparedness to face future health threats.
ADVERTISEMENT
SCROLL TO CONTINUE WITH CONTENT
At the international level, Bio Farma is also active in global collaboration through the developing country vaccine producer network or DCVMN. This involvement aims to ensure access to safe, quality and affordable vaccines for the world community.
In the future, Bio Farma will continue to be directed to strengthen its focus on vaccine development as its core business to support national health resilience. The government emphasizes the importance of producing affordable but high quality vaccines to be able to answer the challenges of pandemics and other infectious diseases. With a combination of innovation, large production capacity and global collaboration, Bio Farma is expected to remain at the forefront in maintaining Indonesia’s sovereignty and health resilience.
(akn/ega)
